- Category: Experimental HCV Drugs
- Published on Friday, 25 September 2015 00:00
- Written by Achillion
Achillion Pharmaceuticals' experimental NS5A inhibitor odalasvir (ACH-3102) plus Gilead Science's sofosbuvir (Sovaldi), taken without ribavirin, produced sustained virological response at 12 weeks post-treatment in all previously untreated genotype 1 hepatitis C patients treated for 6 or 8 weeks in a small Phase 2 study, according to a recent company announcement. Treatment was safe and well-tolerated.